Evolus Phase III European - Canadian Head-to-Head Trial of prabotulinumtoxinA Compared to Botox® Meets Primary Endpoint
April 05, 2018 07:30 ET
|
Evolus
IRVINE, Calif., April 05, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS) (“Evolus”), a medical aesthetics company focused on delivering advanced aesthetic procedures and treatments to...
Evolus Reports Fourth Quarter and Full Year 2017 Financial Results
March 29, 2018 07:30 ET
|
Evolus
IRVINE, Calif., March 29, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS) (“Evolus” or the “Company”), a medical aesthetics company focused on delivering advanced aesthetic procedures and...